Advancing Healthcare Through Minimally Invasive Surgery: Terumo India's Innovations & Initiatives
Minimally Invasive Surgery (MIS), also known as laparoscopic or keyhole surgery, involves performing surgical procedures through small incisions using specialised instruments and cameras. This approach minimises trauma to the body, reduces post-operative pain, and accelerates recovery compared to traditional open surgery. Over the years, MIS has become increasingly popular across various medical specialties, offering patients safer and more effective treatment options.
In an exclusive conversation with BW Healthcare World, Nitin Stephen Abel, Senior Director at Terumo Interventional Systems, provided valuable insights into the groundbreaking advancements in minimally invasive surgery (MIS) technology and Terumo India's pivotal role in shaping the healthcare landscape.
Advancements in MIS Technology:
Discussing recent strides in MIS technology, Abel highlighted Terumo's commitment to innovation. He emphasised the introduction of B-TACE therapy for liver cancer management, leveraging the Occlusafe device to precisely deliver chemotherapy drugs to tumors while minimising damage to healthy tissues. This breakthrough therapy has shown promising outcomes, with improved response rates and reduced need for repeat treatments, he stated.
Innovations in Cardiac Care:
Another notable innovation discussed was the Ultimaster Nagomi Drug-Eluting Stent (DES) for coronary artery disease treatment. Abel elaborated on the seamless adaptability of this next-generation DES to various vessel sizes, enhancing navigation through complex arteries and revolutionising cardiac care in India.
Training and Support Programs:
Nitin outlined Terumo's comprehensive initiatives aimed at elevating skills and expertise among healthcare professionals. He highlighted the Terumo India Skill Lab (TISL), offering diverse training models for skill enhancement, and the eTISL knowledge bank, providing online educational resources for healthcare professionals. Additionally, he discussed the TRY The TRI Program and the Cathlab Director program, designed to foster practical learning and improve standards of care in cardiac interventions.
Impact on Patient Outcomes:
Addressing the impact of Terumo's MIS technologies on patient outcomes, he emphasised the focus on minimising physical burden through innovations like Transradial Intervention (TRI). He highlighted benefits such as reduced blood loss, enhanced precision, and expedited recovery, showcasing the transformative potential of MIS in improving healthcare outcomes.
Accessibility and Affordability:
Abel underscored Terumo's commitment to expanding access to advanced medical therapies across India. He discussed initiatives like 'phygital' models for medical education and collaborations with healthcare institutions to address unmet needs and enhance public health, ensuring that advanced healthcare solutions are accessible and affordable to all.
Future Goals and Aspirations:
Reflecting on future goals, Abel expressed Terumo's aspirations to further expand its MIS portfolio and advance healthcare through research and cutting-edge technology. He emphasised the importance of upscaling training initiatives and increasing awareness and adoption of minimally invasive intervention procedures among physicians and patients in India.
In conclusion, he reiterated Terumo's dedication to transforming healthcare through innovation and collaboration. He reaffirmed the company's commitment to advancing medical practices and improving patient outcomes in India and beyond, highlighting Terumo's role as a pioneer in revolutionising healthcare.
